PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31514476-7	2019	The results showed that the plasma levels of TIMP-1 in the group of patients receiving HT were significantly lower than those levels found in the control group after the epirubicin-cyclophosphamide chemotherapy.	Epirubicin	170-180	TIMP metallopeptidase inhibitor 1	Homo sapiens	45-51	
28963609-6	2019	TIMP-1 overexpressing U87MG cells were significantly more resistant than low TIMP-1 expressing clones and parental cells when exposed to SN-38 (TOP1 inhibitor) or epirubicin (TOP2 inhibitor).	Epirubicin	163-173	TIMP metallopeptidase inhibitor 1	Homo sapiens	0-6	
19535243-12	2009	CONCLUSION: Lack of TIMP-1 tumour cell immunoreactivity seems to predict a favourable effect of epirubicin-containing adjuvant therapy in primary breast cancer.	Epirubicin	96-106	TIMP metallopeptidase inhibitor 1	Homo sapiens	20-26	
23570501-2	2013	The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A copy number can be used to predict benefit from epirubicin (E) containing chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil (CMF) treatment.	Epirubicin	215-225	TIMP metallopeptidase inhibitor 1	Homo sapiens	68-107	
23570501-2	2013	The purpose of the present study was to validate prior results that tissue inhibitor of metalloproteinase 1 (TIMP-1) alone or in combination with either HER2 or TOP2A copy number can be used to predict benefit from epirubicin (E) containing chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil (CMF) treatment.	Epirubicin	215-225	TIMP metallopeptidase inhibitor 1	Homo sapiens	109-115	
21684102-4	2011	Our data demonstrated that overexpression of TIMP-1 could significantly decrease the sensitivity of MDA-435 breast cancer cells to epirubicin and paclitaxel.	Epirubicin	131-141	TIMP metallopeptidase inhibitor 1	Homo sapiens	45-51	
21684102-6	2011	Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance.	Epirubicin	61-71	TIMP metallopeptidase inhibitor 1	Homo sapiens	17-23	
21684102-6	2011	Furthermore, the TIMP-1-induced attenuation of the effect of epirubicin and paclitaxel was reversed by the PI3K/Akt chemical inhibitor LY294002 and the NF-kB inhibitor pyrrolidine dithiocarbamate (PDTC), showing that the PI3K/Akt and NF-kB signaling pathway was involved in the TIMP-1-induced effect on chemoresistance.	Epirubicin	61-71	TIMP metallopeptidase inhibitor 1	Homo sapiens	278-284